ExpreS2ion Biotech Holding

ExpreS2ion Biotechnologies expects to publish its full-year report for 2025 (Q4) on 19 February 2026. Later the same day at 09:30, the company’s management will present the results for the financial year, provide an update on business and pipeline developments, and follow up on recent company news in a live online event, which will conclude with a Q&A session.

Dagens aktienyheder med Bang & Olufsen og ExpreS2ion Biotech

We have published an updated one-pager on ExpreS2ion Biotech following early immunogenicity data and dose escalation clearance in the Phase I ES2B-C001 breast cancer vaccine, which begins to de-risk near-term development, alongside the completed TO 11 warrant programme. The note also reflects the malaria licensing agreement with Serum Institute of India, which provides platform validation and limited non-dilutive funding, while ES2B-C001 remains the core value driver.

Dagens aktienyheder 22/12-2025: Gomspace og ExpreS2ion Biotechnologies

ExpreS2ion today reported updated immunogenicity data from the first three patients treated with its HER2-targeted breast cancer vaccine candidate ES2B-C001, alongside confirmation that the independent Data Safety Monitoring Board (DSMB) has reviewed safety data and recommended progression to the next dose cohort in the ongoing Phase I trial.

Today, ExpreS2ion Biotechnologies’ management presented the results for the third quarter of 2025, provided further insights into the recent pipeline developments with focus on the malaria and breast cancer candidates, and shared the latest updates on partnerships agreements signed with SII.

ExpreS2ion Biotechnologies is expected to release its results for the first nine months of 2025 on 13 November 2025. Later the same day at 11:00 CET, the management team will present the financial results and key achievements in a live online presentation. The presentation will be followed by a Q&A session.

Dagens aktienyheder med Alk-Abello, Rovsing, ExpreS2ion Biotechnologies, Trifork og Wirtek

Mød ledelsen i Rovsing, ExpreS2ion Biotechnologies, DFDS, og ALK, og stil spørgsmål til dagens investorpræsentationer

ExpreS2ion Biotech has entered a definitive licensing agreement with the Serum Institute of India (SII) for two blood-stage malaria vaccine candidates, RH5.1 and R78C, built on ExpreS2ion’s proprietary ExpreS2™ production platform. RH5.1 is currently in Phase II trials. An initial term sheet was announced with Serum Institute of India in November 2024, and today’s deal outlines that ExpreS2ion will receive upfront and milestone payments with an accumulated value of a low single-digit EUR amount, and in addition, is eligible for royalties ranging from below 1% to mid-single digits on future net sales.

Dagens aktienyheder med Sampo plc, Columbus, ExpreS2ion Biotechnologies og Wirtek A/S